Condition: Female · Sponsor: Chang Gung Memorial Hospital
Add-on dostarlimab to chemoradiation with etoposide and cisplatin and radiotherapy can improve progression-free survival (PFS) compared with historical controls who were treated with chemoradiation alone in SCNECC
This description comes directly from the study's public registry record.
CHYONG-HUEY CHL LAI · +88633281200#8254 · laich46@cgmh.org.tw
Always discuss trial participation with your own doctor first.
| Chang Gung Memorial Hospital, Linkou Branch | Taoyuan, Taiwan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07336147